ArticleFrontiers in oncology2026
Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients enrolled in phase I oncology clinical trials are expected to survive more than 3 months, yet up to 15% may die before this threshold. Several prognostic scores have been developed to identify patients unlikely to derive benefit from trial participation. We aimed to compare the prognostic performance of five described scores. Methods: This retrospective study included 844 patients treated with immunotherapy in phase I trials at Clínica Universidad de Navarra (2016-2023). Prognostic scores (RMH, GRIm, LIPI, PIPO, ROPRO) were calculated according to their original definitions. Discriminative performance was assessed using Harrell's C-index, 3-month AUC, and time-dependent AUC. Results: Median OS was 9.08 months. All scores demonstrated statistically significant prognostic stratification. C-index values were: RMH 0.58, GRIm 0.55, LIPI 0.66, PIPO 0.63, and ROPRO 0.69. AUC at 3 months was highest for ROPRO (0.76). However, no score identified a subgroup with a median OS below 3 months. Conclusions: All five scores stratified prognosis but failed to select patients with OS below 3 months. These findings challenge their use as rigid exclusion criteria and support their role as stratification factors. New models integrating dynamic clinical or molecular biomarkers are needed to improve patient selection in phase I immunotherapy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.